The national healthcare reform policies are sweeping in like a spring breeze, and Lu Xiangyi Centrifuge is poised for another major collaboration.

　　Starting from September 2018, the medical insurance industry has received increasing attention from the government, and favorable policies have been introduced one after another. Under the wise leadership of the Party, positive news has continued to pour in like a gentle spring breeze. For pharmaceutical manufacturers, this undoubtedly represents a major opportunity to boost industry development!

　　So, what are the new policies for medical insurance in 2018? And what are the reimbursement rates under medical insurance? Let’s take a look together below.

　　 Point 1: The threshold for medical treatment and hospitalization is reduced by 50%!

　　In 2018, the threshold for medical treatment and hospitalization under the Urban and Rural Resident Medical Insurance underwent significant adjustments: the threshold at designated medical institutions of levels one, two, and three was all reduced by half! In other words, even though there’s a minimum spending requirement for medical visits, you can still get reimbursement even if you spend relatively little.

　　 Second point: The reimbursement ratio is raised—again and again and again!

　　After the adjustment of benefits, taking tertiary designated medical institutions as an example, the reimbursement rate for hospitalization for minors and students rose from 65% in 2017 to 70% in 2018; for non-working residents and seniors, the reimbursement rate for hospitalization increased from 55% in 2017 to 60%. Simply put, you’ll have less and less out-of-pocket expenses!

　　These changes in medical insurance benefits for urban and rural residents—benefits that are closely tied to our daily lives—stem from considerations of people’s livelihoods, reflect the sentiments of the people, and arise from public opinion. How could such changes fail to promote the healthy development of the pharmaceutical industry? Of course, the 2018 benefits were diverse and went beyond just this one aspect—for instance, the film “I’m Not the God of Medicine” sparked widespread attention. With the high attention paid by the Party and its leaders, efforts are being made at the root level to address the issues of “limited availability” and “high cost” of cancer drugs. On October 31, 2018, the Beijing Municipal Human Resources and Social Security Bureau took the lead in introducing a new policy benefiting the public: starting November 15 of this year, all 17 cancer drugs—including azacitidine—that have been subject to national negotiations will be fully included in Beijing’s medical insurance reimbursement scope. At the same time, these drugs will also be covered under the outpatient special-disease reimbursement program. (It’s worth noting that, including the anti-cancer drugs already covered, a total of 35 nationally negotiated anti-cancer drugs have been included in Beijing’s medical insurance reimbursement scope, further alleviating the financial burden of medication for patients.) Additionally, Increase the variety of drugs covered under outpatient special disease reimbursement for malignant tumors. To effectively reduce the medical expense burden on patients with serious illnesses.

　　These two new Beijing policies have been officially implemented since November 15, 2018. The Beijing municipal health authority has already made the negotiated drugs publicly available on the Drug Sunshine Procurement Platform according to the payment standards!

　　Finally, with the advancement of high-tech internet technologies, the 2018 social security reform and the new medical insurance policy have brought great news: nationwide network connectivity and cross-regional reimbursement are now finally achievable! This will significantly save time spent on medical visits and reduce unnecessary expenses!

　　The introduction of these favorable policies has provided tremendous impetus to China’s pharmaceutical industry—indeed, this is the case. At a certain pharmaceutical factory, thanks to the new national medical insurance policy reforms that have brought many drugs into the coverage of the medical insurance system, sales have surged. To increase production capacity, the factory needs to boost its procurement of centrifuges. Therefore, they have specially dispatched professional technical personnel to our company, Shanghai Luxiangyi Centrifuge Instrument Co., Ltd., to purchase 12 units of the DL8MS liquid-display high-capacity refrigerated centrifuge. Yes, you’re not mistaken—due to the urgent need to boost production capacity, we’re urgently looking to procure 12 DL8MS liquid-display, high-capacity refrigerated centrifuges.

　　Packing Diagram for DL8MS Liquid-Display Large-Capacity Refrigerated Centrifuge

　　The DL-8MS ultra-large-capacity refrigerated centrifuge, manufactured by Shanghai Luxiangyi Centrifuge Instrument Co., Ltd., is specially designed for customers with high-volume requirements. This model boasts a large sample-processing capacity and is the first choice for institutions such as central blood banks, pharmaceutical companies, and bioengineering facilities. The DL-8MS features a large-screen LCD display, while the DL-8M uses a digital display; both models offer a user-friendly interface and are simple and convenient to operate. Its maximum capacity reaches 2400 ml × 6, allowing a single run to process up to 14,400 ml of samples. The centrifuge offers a variety of rotor options to meet different customer needs, enabling it to separate 12 triple-bag units of 400 ml each in a single run—making it the domestic centrifuge capable of separating the largest number of blood bags. Equipped with 2400 ml centrifuge tubes, it can process up to 14,400 ml of reagents per run. The centrifuge employs microcomputer control and is driven by a high-torque AC variable-frequency motor, ensuring stable operation, low noise levels, and high rotational speed accuracy. It utilizes an imported high-performance compressor unit and environmentally friendly R404a refrigerant that meets stringent environmental standards and delivers excellent cooling performance. The touch-panel interface allows for programmable operation, and host operating parameters can be set according to specific needs and automatically saved. Real-time conversion and setting between rpm and RCF values are quick and convenient. The centrifuge is equipped with an electronic door lock featuring multiple protective functions, including automatic door-locking, overspeed protection, overtemperature protection, and imbalance detection. It also includes an automatic alarm system for fault detection, ensuring safety and reliability. Additionally, the centrifuge provides 10 pre-programmed acceleration/deceleration curves, allowing users to customize the acceleration and deceleration times as needed. Therefore, this centrifuge is ideally suited to meet the production demands of pharmaceutical manufacturers.

　　To ensure the customer’s production schedule, Shanghai Luxiangyi Centrifuge Instrument Co., Ltd. actively communicated with the customer after signing the contract to gain a detailed understanding of their product requirements. The centrifuge production workshop further accelerated its production pace and successfully manufactured 12 DL8MS liquid-display high-capacity refrigerated centrifuges that the customer had ordered. Each centrifuge underwent rigorous factory testing, and then was carefully packaged in sealed wooden crates to prevent any damage during transportation. After confirming that the packaging was secure and proper, the centrifuges were transported using appropriately sized large trucks!

　　DL8MS liquid-display large-capacity refrigerated centrifuge—ready to be loaded and shipped.

　　Shanghai Luxiangyi Centrifuge Instrument Co., Ltd., leveraging years of manufacturing and market experience, actively collaborates with customers and strives to meet their needs. The two sides successfully concluded this transaction through a pleasant and productive discussion. Centrifuge We’ve successfully collaborated on this order and reached a high degree of consensus. We’re grateful for the new national medical insurance policy reforms, which have enabled our country’s medical insurance and pharmaceutical industries to develop more effectively and steadily!